Humacyte Publication in the Journal of Vascular Surgery Vascular Science Reports the Human Acellular Vessel Remains Durable at Six Years in Patients with Peripheral Artery Disease

Humacyte Publication in the Journal of Vascular Surgery Vascular Science Reports the Human Acellular Vessel Remains Durable at Six Years in Patients with Peripheral Artery Disease

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced the publication of '6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass,' in the Journal of Vascular Surgery - Vascular Science. The publication describes the long-term analysis of the Company's Phase 2 clinical trial evaluating the bioengineered HAV as a conduit in patients with symptomatic peripheral …